Genistein in Treatment of Metastatic Colorectal Cancer

Phase 1

Completed

• Conditions: Colon Cancer; Rectal Cancer; Colorectal Cancer
• Interventions: Drug: Genistein

• Registration Number: NCT01985763
• Lead Sponsor: Sofya Pintova

Brief Summary

Colorectal neoplasms are the third most common malignancies in the United States. Patients with metastatic (stage IV) colorectal cancer have a median life expectancy of 2 years. The response rates to chemotherapy range from 35-40%.

Epidemiologic evidence suggests that soy compounds may reduce the incidence of colorectal cancers. Laboratory analyses demonstrate that genistein, a soy-derived compound, may inhibit Wnt signaling, a pathway activated in majority of colorectal cancers. Laboratory observations also demonstrate that genistein may augment growth inhibition when combined with chemotherapeutic agents of 5-Fluorouracil and platinum compounds.

Based on pre-clinical data the investigators hypothesize that combining genistein with the standard of care chemotherapeutic regimens will reduce chemotherapy resistance and improve response rates in patients. The aim of the study is to add genistein to the regimens of FOLFOX or FOLFOX-Avastin in patients with newly diagnosed stage IV colon or rectal neoplasms.

Detailed Description

OBJECTIVES:

Primary

* Evaluate the tolerability of genistein when combined with chemotherapy

Secondary:

* Evaluate Response Rate (RR) as measured by the radiologic RECIST criteria

* Evaluate Progression Free Survival (PFS)

Study Timeline

• Study Start: 2013-11
• Study First Submitted: 2013-11-09
• Study First Submitted QC: 2013-11-14
• Study First Posted: 2013-11-15
• Primary Completion: 2017-01-19
• Study Completion: 2018-10-31
• Results First Submitted: 2019-03-26
• Status Verified: 2019-04
• Results First Submitted QC: 2019-04-18
• Last Update Submitted: 2019-04-18
• Results First Posted: 2019-05-10
• Last Update Posted: 2019-05-10

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 13

Inclusion Criteria

• Adult male and female patients ≥18 years old

• Have pathologically confirmed colon or rectal carcinoma

• Have metastatic (stage IV) disease

• Have a plan by treating physician to receive FOLFOX or FOLFOX-Avastin

• Have an Eastern Cooperative Oncology Group (ECOG) performance status ≤2

• Have adequate hematopoietic, hepatic and renal function

  1. Hematopoietic function

     • Hemoglobin ≥10g/dL
     • Absolute Neutrophil Count(ANC) ≥1,500cells/mm2
     • Platelet Count ≥100,000/µL

  2. Hepatic Function

     • Total bilirubin ≤ 1.5x the upper limit of normal
     • ALT and AST must each be ≤2,5x the upper limits of normal

  3. Renal Function

     • Estimated creatinine clearance (Clcr) ≥30 mL/minute

• Are not pregnant and do not plan to become pregnant

Read More

Exclusion Criteria

• Prior systemic chemotherapy for metastatic disease
• History of breast cancer, endometrial cancer or ovarian cancer or taking aromatase inhibitors or selective estrogen receptor modulators
• Patients taking MAO-inhibitors
• History of myocardial infarctions or cardiac stent placement less than 1 year before recruitment into the study
• Unable to give informed consent or comply with clinical trial requirements
• Uncontrolled hypertension
• History of clinically significant GI bleeding within prior 2 months prior to enrollment
• Presence of GI fistula
• Prior history of bowel perforation
• History of CNS thrombotic/embolic or ischemic events
• Have past or current, acute or chronic concurrent medical condition/illness or therapy that, in the opinion of the investigator, would make the subject unsuitable for the clinical trial or unable to comply with the follow up visits.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Genistein	Genistein	Genistein combined with FOLFOX or FOLFOX-Avastin Genistein 60mg/day orally for 7 days every 2 weeks. Genistein will be administered beginning 4 days prior to FOLFOX or FOLFOX-Avastin and continuing the 3 days of chemotherapy.

Primary Outcome Measures

Name	Time	Method
Number of Adverse Events	up to 6 months	Number of adverse events to assess tolerability of genistein treatment. Evaluation of side effects conducted every 14 days before each chemotherapy/genistein cycle.
Percent Change in Tumor Size	end of Cycle 6	Percent change in tumor size after cycle 6. Each cycle is 21 days.

Secondary Outcome Measures

Name	Time	Method
Response Rate RECIST Criteria	end of Cycle 6	Response Rate (RR) as measured by radiologic RECIST criteria. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm.; Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.; Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Number of Participants With an Overall Response Rate (ORR)	up to 50 months	Number of participants with an ORR - the portion of patients with a tumor size reduction of a predefined amount for a minimum time period
Best Overall Response Rate RECIST Criteria	up to 50 months	Best Overall Response Rate (ORR) as measured by radiologic RECIST criteria. The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.; SD - target lesion SD, non target lesions Non-PD, and no new lesions. PR - target lesion CR, non target lesions Incomplete response/SD and no new lesions; or target lesion PR, non target lesions Non-PD, and no new lesions.; PD - target lesions PD, non target lesions Any, can have new lesions; or target lesions Any, non target lesions PD, can have new lesions; or target lesions Any, non target lesions Any, have new lesions.
Number of Participants With Best Overall Response Rate (ORR)	up to 50 months	The number of participants with best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started). In general, the patient's best response assignment will depend on the achievement of both measurement and confirmation criteria.
Progression Free Survival (PFS)	up to 50 months	Patients monitored for progression. Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse.
Percent of Patients With Progression Free Survival (PFS) at 6 Months and 12 Months	6 month and 12 month	Patients monitored for progression during the study period and 1 year following.; Progression-free survival (PFS) is the length of time during and after the treatment that a patient lives with the disease but it does not get worse.
Overall Survival (OS)	up to 50 months	Overall Survival - Number of months still living since baseline

Trial Locations

Locations (1)

Icahn School of Medicine at Mount Sinai; 🇺🇸 New York, New York, United States